Amgen presents Sjogren data: Amgen stock gets a 1.8-point test
Published on 10/28/2026 at 11:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSClinical data and shareholder dates
- Amgen declared a USD 2.52 per share fourth-quarter dividend on October 27, 2026.
- OASIZ-301 reduced disease activity by 1.8 points versus placebo at Week 48.
- Amgen stock traded at EUR 401.05 at 11:10 a.m. Berlin time at Lang & Schwarz on October 28, 2026.
Amgen stock (ISIN US0311621009) was trading at EUR 401.05 at Lang & Schwarz on October 28, 2026 at 11:10 a.m. Berlin time. On October 27, 2026, Amgen announced new Phase 3 OASIZ-301 data for dazodalibep in Sjogren's disease, giving the stock a fresh clinical-data focus.
What does the trial mean?
The company said Week 48 results showed a least-squares mean disease-activity change of minus 5.6 points for the dosing regimen given every four weeks, versus minus 3.8 points for placebo. The difference was therefore 1.8 points. The 12-week regimen produced a minus 5.2-point change, a 1.4-point difference versus placebo.
The release also reported a baseline ESSDAI score of 10.2 and statistically significant improvements in patient-reported dryness for the four-week regimen. Amgen plans to present the late-breaking results as Abstract 22 at the American College of Rheumatology Convergence on November 11, 2026.
Dividend sets a second date
Amgen's board declared a USD 2.52 per share dividend for the fourth quarter of 2026 on October 27, 2026, according to the company's dividend release. The payment is scheduled for December 11, 2026, to shareholders of record on November 20, 2026.
For investors, the two announcements place different dates beside the same stock. The dividend supplies a defined cash-distribution timetable, while the Sjogren's data point to an upcoming clinical presentation with quantified trial results. The ACR program also includes UPLIZNA, KRYSTEXXA and TAVNEOS data.
Upcoming company dates
Amgen's ACR presentation is scheduled for November 11, 2026, with the abstract listed for 8:45 to 9:00 a.m. ET. The dividend payment date is December 11, 2026, while the November 20 record date determines eligibility under the company's announcement.
Stock price in Berlin
The Lang & Schwarz quote places Amgen at EUR 401.05 during the regular Xetra trading phase on October 28, 2026. The quote was captured at 11:10 a.m. Berlin time and is presented without a daily percentage because a dated Xetra closing reference could not be established from the required exchange route.
The further course of trading is shown by the continuously updated real-time quote of Amgen stock.
Amgen stock facts
- Company: Amgen Inc.
- ISIN: US0311621009
- Ticker: AMGN
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 28, 2026, 11:10 a.m. Berlin time): EUR 401.05
- Sector / Industry: Healthcare / Drug Manufacturers - General
- Index membership: Nasdaq-100
Market context: Market report Nasdaq Composite.
